"I haven't a clue about what to expect from [President-elect Donald] Trump in 2017. He says, 'Oh, we're going to do something on pricing,' and the markets go down and then at the end of the day the markets go back up. As far as I'm concerned, it's business as usual until it changes. I have no other way to operate, because if it's not business as usual the universe of things that could happen is so great that I can't possibly handicap it."
Jay Lichter, president and CEO of COI Pharmaceuticals Inc. and managing director at Avalon Ventures

"Data by itself is amazing, but it is frozen knowledge. It is up to us as entrepreneurs to use our energies to melt this data into meaningful projects."
Atul Butte, director of the Institute for Computational Health Sciences and professor of pediatrics at the University of California San Francisco, a panelist on the roundtable on Investing in Data: The Future of Health Delivery at the J.P. Morgan Healthcare conference

"Approximately 50 percent of melanomas harbor an activating mutation in the BRAF gene. BRAF kinase inhibitors such as vemurafenib have significantly improved response rates and overall and progression-free survival in melanoma patients with BRAF mutations."
Kiyoko Fukami, a professor in the Laboratory of Genome and Biosignals at Tokyo University of Pharmacy and Life Sciences, and leader of a study that has identified two promising and selective candidate therapeutic targets that could prove important in the development of new treatments aimed at overcoming drug resistance in melanoma